. 2022 Jul 6;33(2):19–26. doi: 10.1294/jes.33.19

Table 2. Comparison of gene expression and percentages of positive cells for tenogenic markers among treatments.

Group	Comparative gene expression (Mean ± SE)				Percentage of positive cells

	TNMD	SCX	DCN	TNC	COL1
Control	1.00 ± 0.00^a	1.00 ± 0.00^a	1.00 ± 0.00^a	1.00 ± 0.00^a	0.00% (0/153)^a
BMP	11.58 ± 4.34^b	1.36 ± 0.21^a	1.53 ± 0.12^a	1.43 ± 0.17^a	50.32% (78/155)^b
BMPKY1	52.95 ± 19.38^c	2.16 ± 0.36^b	1.60 ± 0.12^a	1.58 ± 0.15^a	53.72% (65/121)^bc
BMPKY3	1.81 ± 0.63^a	0.98 ± 0.05^a	1.36 ± 0.31^a	1.26 ± 0.19^a	65.65% (86/131)^c
BMPKY5	1.55 ± 0.04^a	0.86 ± 0.07^a	3.32 ± 0.51^b	3.27 ± 0.37^b	55.13% (86/156)^bc

Average gene expression was calculated for the three cell lines and repeated in triplicate. ^a–cSignificant difference (P<0.05). TNMD: Tenomodulin; SCX: Scleraxis; DCN: Decorin; TNC: Tenascin-C; COL1: type I collagen.